Adaptive Biotechnologies to Report Fourth Quarter and Full Year 2023 Financial Results on February 14, 2024

Rhea-AI Summary

Adaptive Biotechnologies Corporation (ADPT) will report Q4 and full year 2023 financial results on February 14, 2024. The webcast will be available on their website. The company focuses on translating adaptive immune system genetics into clinical products for disease diagnosis and treatment.

SEATTLE, Jan. 29, 2024 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will report financial results for the fourth quarter and full year 2023 after market close on Wednesday, February 14, 2024. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

Live audio of the webcast will be available on the “Investors” section of the company website at: www.adaptivebiotech.com. The webcast will be archived and available for replay within 24 hours after the event.

About Adaptive Biotechnologies

Adaptive Biotechnologies (“we” or “our”) is a commercial-stage biotechnology company focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. We believe the adaptive immune system is nature’s most finely tuned diagnostic and therapeutic for most diseases, but the inability to decode it has prevented the medical community from fully leveraging its capabilities. Our proprietary immune medicine platform reveals and translates the massive genetics of the adaptive immune system with scale, precision and speed. We apply our platform to partner with biopharmaceutical companies, inform drug development, and develop clinical diagnostics across our two business areas: Minimal Residual Disease (MRD) and Immune Medicine. Our commercial products and clinical pipeline enable the diagnosis, monitoring, and treatment of diseases such as cancer, autoimmune disorders, and infectious diseases. Our goal is to develop and commercialize immune-driven clinical products tailored to each individual patient.

ADAPTIVE INVESTORS
Karina Calzadilla, Vice President, Investor Relations
201-396-1687
investors@adaptivebiotech.com

ADAPTIVE MEDIA
Erica Jones, Associate Director, Corporate Communications
206-279-2423
media@adaptivebiotech.com

FAQ

When will Adaptive Biotechnologies Corporation report its Q4 and full year 2023 financial results?

Adaptive Biotechnologies Corporation will report its Q4 and full year 2023 financial results after market close on February 14, 2024.

Where can I access the webcast of the conference call?

The webcast will be available on the 'Investors' section of the company website at www.adaptivebiotech.com.

What does Adaptive Biotechnologies Corporation focus on?

Adaptive Biotechnologies Corporation aims to translate the genetics of the adaptive immune system into clinical products for disease diagnosis and treatment.